Myeloma Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People aged 18 years or older
- People who have agreed to take part and signed a consent form
- People who are covered by a social security (health insurance) scheme
- Group 1: People who have been newly diagnosed with multiple myeloma (a type of blood cancer) and whose doctor has determined they need a blood clot prevention medication called Apixaban
- Group 2: People who are scheduled to have a total knee replacement surgery and whose doctor has determined they need Apixaban for blood clot prevention
Who may not be able to join:
- People who are already taking anticoagulant (blood thinning) medication at treatment-level doses (rather than prevention-level doses)
- People for whom Apixaban is medically unsuitable or not recommended
- People who are pregnant or breastfeeding
- People who do not wish to sign the consent form
- People who are under legal protection or guardianship (confirm with trial site)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Emilie CHALAYER, MD, CHU de Saint-Etienne
Phone: (0)477822814
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Endogenous Thrombin potential (nM.min)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.